Idiopathic intracranial hypertension (IIH), also known as “pseudotumor cerebri” (PTC), is a medical condition characterized by an increase in intracranial pressure (ICP) without radiographic evidence of dilated ventricles or mass lesion and normal CSF content. The increase in ICP typically manifests as visual disturbances, papilledema and visual loss, headache, and/or pulsatile tinnitus. Current medical treatment options include carbonic anhydrase inhibitors such as acetazolamide, furosemide, and topiramate. Procedures such as

Transverse venous stenting for the treatment of idiopathic intracranial hypertension, or pseudotumor cerebri

Justin M. Cappuzzo, MD, Ryan M. Hess, BS, John F. Morrison, MD, Jason M. Davies, MD, PhD, Kenneth V. Snyder, MD, PhD, Elad I. Levy, MD, MBA, and Adnan H. Siddiqui, MD, PhD

Departments of 1Neurosurgery, 2Biomedical Informatics, 3Neurology, and 4Radiology, Jacobs School of Medicine at the University at Buffalo; 5Department of Neurosurgery, Gates Vascular Institute at Kaleida Health; 6Canon Stroke and Vascular Research Center at the University at Buffalo; and 7Jacobs Institute, Buffalo, New York

OBJECTIVE Idiopathic intracranial hypertension (IIH) is a commonly occurring disease, particularly among young women of child-bearing age. The underlying pathophysiology for this disease has remained largely unclear; however, the recent literature suggests that focal outflow obstruction of the transverse sinus may be the cause. The purpose of this study was to report one group’s early experience with transverse venous sinus stenting in the treatment of IIH and assess its effectiveness.

METHODS The authors performed a retrospective chart review to identify patients who had undergone stenting of an outflow-obstructed transverse venous sinus for the treatment of IIH at Gates Vascular Institute between January 2015 and November 2017. Patient demographic data of interest included age, sex, BMI, and history of smoking, hypertension, obstructive sleep apnea, hormonal contraceptive use, and acetazolamide therapy. Each patient’s presenting signs and symptoms and whether those symptoms improved with treatment were reviewed. The average opening lumbar puncture (LP) pressure preprocedure, average pressure gradient across the obstructed segment prior to stenting, treatment failure rate (need for shunt placement), and mean follow-up period were calculated.

RESULTS Of the 18 patients who had undergone transverse venous stenting for IIH, 16 (88.9%) were women. The mean age of all the patients was 38.3 years (median 38 years). Mean BMI was 34.2 kg/m² (median 33.9 kg/m²). Presenting symptoms were headache (16 patients [88.9%]), visual disturbances (13 patients [72.2%]), papilledema (8 patients [44.4%]), tinnitus (3 patients [16.7%]), and auditory bruit (3 patients [16.7%]). The mean opening LP pressure preprocedure was 35.6 cm H₂O (median 32 cm H₂O). The mean pressure gradient measured proximally and distally to the area of focal obstruction within the transverse sinus was 16.5 cm H₂O (median 15 cm H₂O). Postprocedurally, 14 patients (77.8%) continued to have headaches; 6 (33.3%) continued to have visual disturbances. No patients continued to have auditory bruit (0%) or papilledema (0%). One patient (5.6%) had new-onset tinnitus postprocedure. Overall improvement of symptoms was noted in 16 patients (88.9%) postprocedure, with 1 patient (5.6%) requiring shunt placement and 2 other patients (11.1%) requiring postprocedural LP to monitor intracranial pressure to determine candidacy for further surgical interventions to treat residual symptoms. The mean duration of follow-up was 194.2 days.

CONCLUSIONS Transverse sinus stenting is a rapidly developing technique that has shown good effectiveness and safety in the literature. Authors of the present study found that stenting a flow-obstructed transverse sinus in patients with IIH was a safe and effective way to treat the condition.

https://thejns.org/doi/abs/10.3171/2018.5.FOCUS18102

KEYWORDS stenting; idiopathic intracranial hypertension; pseudotumor; transverse sinus

ABBREVIATIONS ICP = intracranial pressure; IIH = idiopathic intracranial hypertension; LP = lumbar puncture; PTC = pseudotumor cerebri; VSOO = venous sinus outflow obstruction.


INCLUDE WHEN CITING DOI: 10.3171/2018.5.FOCUS18102.
lumbar puncture (LP) are traditionally used to decrease ICP, and additional procedures such as optic nerve sheath fenestration can be used for visual symptom relief.12

The pathophysiology of IIH is unclear. It has been linked to increased CSF production, reduced CSF absorption, and changes in vitamin A metabolism. Given the large number of patients with IIH who have venous sinus outflow obstruction (VSOO), the latter has been proposed as a possible mechanism leading to the development of the increased ICP seen in patients.2 Thus, venous sinus stenting has recently emerged as a potential treatment modality for IIH. Studies have shown that it is a safe and effective way to reduce ICP and alleviate symptoms.1,3,4

The purpose of this study was to report our early experience with transverse venous sinus stenting in the treatment of IIH and assess its effectiveness.

Methods

After obtaining institutional review board approval, we performed a retrospective review of the medical records of patients who had undergone stenting of a stenotic transverse venous sinus for the treatment of IIH at Gates Vascular Institute between January 2015 and November 2017. We reviewed our electronic medical records system to obtain basic demographic data, medical history, presenting signs and symptoms, pre-stenting procedures for IIH treatment, procedure details, and postprocedure follow-up. Medical history included height, weight, BMI, smoking status, caffeine use, comorbid medical conditions, history of bariatric surgery, and medications taken at home. Pre-stenting treatment for IIH was also recorded and included medical treatment such as carbonic anhydrase inhibitors, as well as interventional procedures such as LP with the corresponding opening pressure, shunt placement, and optic nerve sheath fenestration.

Recorded details of the stenting procedure included the pressure gradient measured proximally and distally to the focal area of obstruction. Postprocedural variables were also analyzed, including complications, postprocedural signs and symptoms, and whether or not a patient’s symptoms had improved. Post–stent deployment pressures were not available for collection in all cases. The duration of each patient’s postprocedural course was measured by counting the number of days between the date of the procedure and the most recent clinic visit. This was defined as our follow-up period. The effectiveness of the procedure was analyzed by examining each patient’s initial presenting signs and symptoms and noting if they had improved, worsened, or remained unchanged during the follow-up period. Additionally, the need for postoperative shunt placement, optic nerve sheath fenestration, or LP was recorded to determine if remaining symptoms were severe enough to warrant further intervention. Of note, all patients who received transverse sinus stents were placed on dual antiplatelet therapy with aspirin, 325 mg daily, and clopidogrel, 75 mg daily, for 3 months and aspirin monotherapy thereafter.

Surgical Technique

The patient is properly identified, and verbal and written consent are verified. The patient is brought to the angiography suite and positioned supine on the table. The patient is prepared and draped with exposure of the right groin area for access to the right femoral artery. Local anesthesia is administered, regardless of whether conscious sedation or general endotracheal intubation is used. The decision to administer general anesthesia or conscious sedation is a multidisciplinary process that takes into account the patient’s ability to tolerate the procedure in an awake state, as well as the anesthesiologist’s concerns. After the administration of sedatives, a microcatheter kit is used to access the right common femoral vein. A modified Seldinger technique is used to place an 8-Fr short sheath.

A 6-Fr catheter is typically used, such as the NeuronMax catheter (Penumbra Inc.), to introduce over the 0.035-inch Glidewire (Terumo Interventional). The entire system is advanced through the inferior vena cava into the superior vena cava and into either the right common jugular vein or the right internal jugular vein, depending on sinus dominance, based on preoperative imaging, until it reaches the level of the jugular bulb. A 3- to 4-Fr catheter such as the 3Max microcatheter (Penumbra Inc.) is used through the 6-Fr long guide to access the anterior sagittal sinus over the 0.035-inch Glidewire. A venogram of the anterior sagittal sinus is obtained to evaluate the anatomy of the entire major venous drainage system. The contralateral sigmoid sinus and transverse sinus are similarly cannulated using a 3- to 4-Fr catheter such as the 3Max microcatheter. After venography, venous pressure is measured at prescribed points along the venous system to see if there is a gradient between 2 points.

Single fluoroscopic images are obtained at each measured point as the microcatheter is withdrawn, and the measurements are recorded. The contralateral venous sinuses are then accessed with the catheter by crossing the torcular with the wire. Measurements are taken from the contralateral jugular bulb backward through the sigmoid sinus up into the transverse sinus and again in the torcular and across to the ipsilateral venous sinus system.

An area of stenosis as would be expected in the arterial system is rarely identified. Instead, the venography is almost always underwhelming. The pressure gradient is key to identifying the area of obstruction. We have occasionally performed intravascular ultrasound imaging to gauge the area of obstruction and pressure gradient.8 Most lesions here appear to be mobile, potentially tissue flaps or arachnoid granulations. In the past, we have also tried balloon angioplasty and, invariably, these maneuvers result in the obstructing elements being temporarily displaced during angioplasty and then returning to their obstructed state. That is why we use primary stenting as a means to permanently displace the obstructing tissue elements.

After the pressure gradient is located, a Treasure Floppy 0.018-inch peripheral guidewire (Asahi-Intecc Co.) is advanced with the stent, such as a Zilver 8 × 60–inch stent (Cook Medical), as depicted in Fig. 1. The stent is unsheathed from the 6-Fr guide catheter and deployed to cover the focal area of obstruction within the transverse sinus, as shown by the illustration in Fig. 2. Venous pressure monitoring is performed to confirm decreased pressure gradients. The wires and catheters are subsequently removed.
The patient is evaluated for signs of hematoma, hemorrhage, or loss of distal pulses and discharged after an overnight observation period.

Results

During the study period, 19 patients were selected for transvenous stenting for IIH. One patient was excluded from analysis because of the inability to pass the catheter through the sinus and perform the procedure. Among the 18 patients who underwent the stenting procedure, the mean age was 38.3 years (median 38 years) and 16 (88.9%) patients were women (Table 1). The mean BMI was 34.2 kg/m² (median 33.9 kg/m²). Ten (55.6%) patients had a history of smoking, 3 (16.7%) had a history of hypertension, 3 (16.7%) had a history of obstructive sleep apnea, and 5 (27.8%) had a history of hormonal contraceptive use. The presenting signs and symptoms in the order of the most to the least common were as follows: headache (16 patients [88.9%]), visual disturbances (13 patients [72.2%]), papilledema (7 patients [38.9%]), tinnitus (3 patients [16.7%]), and auditory bruit (3 patients [16.7%]). The mean opening pressure at the time of LP was 35.6 cm H₂O (median 32 cm H₂O). The mean pressure gradient, measured proximally and distally to the area of focal stenosis within the transverse sinus, was 16.5 cm H₂O (median 15 cm H₂O), which included all but one patient for whom the data were not available. The pressure across the transverse sinus on the side contralateral to the stent was only available for 11 of the 18 patients studied (Table 2). The mean pressure on the contralateral side was noted to be 19.4 cm H₂O (median 18.0 cm H₂O).

Among the 18 patients who underwent transverse sinus stenting, 14 (77.8%) continued to have headaches and 6 (33.3%) continued to have visual disturbances postprocedurally. No patients continued to have auditory bruit or papilledema. One patient (5.6%) had new-onset tinnitus postprocedurally. In total, 16 (88.9%) patients noted improvement in their presenting symptoms or signs following transverse sinus stenting; however, 1 patient (5.6%) eventually required shunt placement and 2 other patients (11.1%) underwent postprocedural LP to confirm normalization of ICP to determine the need for further surgical interventions to treat residual symptoms. After undergoing stenting, one patient’s opening pressure decreased from 40 to 24 cm H₂O, and the other patient’s opening pressure decreased from 27 to 16 cm H₂O. The mean follow-up period was 194.2 days (range 22–776 days).

Discussion

Idiopathic intracranial hypertension is a relatively common disease, with most recent studies noting an incidence of approximately 0.9 cases per 100,000 individuals in the general population. This number increases to 19 per 100,000 individuals when narrowed to women aged 20–44 years who are 20% over their ideal weight. Although the disease primarily affects young, obese women, it can also affect men and children. Our study results were similar to those in other studies, with both a female predominance (88.9%) and a mean age of 38.3 years (median 38 years). The mean BMI in our study was 34.2 kg/m² (median 33.9 kg/m²), which is also consistent with the cited epidemiological data.

The disease most commonly manifests with headache in upwards of 90% of cases; however, other signs and symptoms are often present. The second most common symptom is visual disturbances, which are reported in upwards of 70% of patients and are most frequently transient in nature. Tinnitus and auditory bruits, otherwise referred to as “pulsatile tinnitus,” are also commonly encountered symptoms. In our experience, headache was the most common presenting symptom, affecting 88.9% of patients, followed by visual disturbances (72.2%) and tinnitus (16.7%) and au-
Secondary PTC implies that there is an identifiable cause for the ICP elevation, ranging from VSOO to metabolic in cause.\(^1\)\(^3\) There is an ongoing debate about whether the cause of IIH is truly VSOO. If it is, there is a recognizable cause for the ICP elevation, and it would be classified under secondary PTC.

The diagnosis of PTC is typically made with a CSF pressure > 20–25 cm H\(_2\)O, a normal CSF profile, no focal neurological deficits other than ICP elevation-induced cranial neuropathies such as cranial nerve VI palsy, and normal radiographs of the brain.\(^8\) Often, LP can show pressures as high as 30–40 cm H\(_2\)O. Computed tomography venography or MR venography can also be performed to evaluate for VSOO. Typically, these noninvasive modalities fail to show abnormalities despite significant pressure gradients discovered during venous angiography. It is rare to identify a lesion on MR angiography and CT angiography that is relevant or significant during angiography or pressure measurement.

Traditional management for PTC has included carbonic anhydrase inhibitors such as acetazolamide. In medically refractory cases, more-invasive procedures such as LP and optic nerve sheath fenestration have been used.\(^4\) Given that one of the proposed pathophysiological causes of pseudotumor is VSOO, there has been a movement toward using cerebral angiography to look for stenosis in symptomatic patients. Likewise, recent advances in interventional neuroendovascular radiology have caused some to propose venous sinus stenting as a possible treatment for pseudotumor. It should be noted that angiography alone, whether arterial to evaluate venous outflow or direct through venous catheterization, is inadequate to identify lesions that appear to create a significant pressure gradient; therefore, pressures must be measured.

In 2011, Ahmed et al. published a study detailing their experience with 46 patients who underwent stenting for IIH.\(^1\) Their patient population consisted of those who remained symptomatic despite maximal medical therapy or had fulminant IIH, in addition to having either bilateral VSOO or a single hypoplastic sinus with stenosis of the contralateral side. They reported that all 46 patients experienced an immediate relief in the pressure gradient across the stenosis that correlated with a rapid reduction in IIH symptoms and papilledema. After a follow-up ranging from 2 months to 9 years, 43 patients were cured of all IIH symptoms, with the remaining 3 having residual headache without associated changes in venous pressure.

Similarly, Dinkin and Patsalides reported success in their case series of 13 patients who were refractory to or unable to tolerate medical therapy or had fulminant visual field loss and who underwent venous sinus stenting for IIH.\(^4\) They reported 100% resolution in pulse-synchronous tinnitus, diplopia, and transient visual obscuration. Headache resolved in 84.7% of the patients. Reported complications included retroperitoneal hemorrhage, transient head or pelvic pain, and a single instance of allergic reaction to contrast material.

The results of our case series followed a similar trend of symptomatic improvement following venous sinus stenting. In our study, 88.9% of patients experienced some or total improvement in their symptoms following the stent-
<table>
<thead>
<tr>
<th>Case No.</th>
<th>HA</th>
<th>Visual Changes</th>
<th>Papill</th>
<th>Tinnitus</th>
<th>Auditory Bruit</th>
<th>Other Preop Sxs &amp; Signs</th>
<th>LP Opening Pressure (cm H2O)</th>
<th>Stenotic Sinus Pressure Gradient (cm H2O)</th>
<th>Contralat Sinus Pressure (cm H2O)</th>
<th>Postop Exam Sxs</th>
<th>Postop Shunt Placement</th>
<th>Postop Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1/1</td>
<td>1/0</td>
<td>1/0</td>
<td>0/0</td>
<td>0</td>
<td>0</td>
<td>28</td>
<td>16</td>
<td>18</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>1/1</td>
<td>1/0</td>
<td>1/0</td>
<td>0/0</td>
<td>0</td>
<td>Ptosis</td>
<td>44</td>
<td>11</td>
<td>24</td>
<td>Venous pulsations on fundoscopic exam; other Sxs: photophobia, phonophobia</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>1/1</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>Nausea</td>
<td>50</td>
<td>15</td>
<td>NA</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>1/0</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>0</td>
<td>34</td>
<td>12</td>
<td>17</td>
<td>Normal; other Sxs: dizziness</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>1/1</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>1/0</td>
<td>Photophobia, phono-phobia, nausea</td>
<td>40</td>
<td>10</td>
<td>21</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>1/1</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>0</td>
<td>36</td>
<td>25</td>
<td>NA</td>
<td>20/50 visual fields; other Sxs: photophobia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>1/1</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>Visual acuity unavailable</td>
<td>35</td>
<td>15</td>
<td>NA</td>
<td>20/200 rt eye, 20/100 lt eye</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>1/1</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>0</td>
<td>31</td>
<td>15</td>
<td>NA</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>9</td>
<td>1/1</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>Facial numbness</td>
<td>32</td>
<td>10</td>
<td>25</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>10</td>
<td>1/1</td>
<td>0/0</td>
<td>1/0</td>
<td>1/0</td>
<td>0</td>
<td>0</td>
<td>19</td>
<td>20</td>
<td>NA</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>11</td>
<td>1/1</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>0</td>
<td>34</td>
<td>25</td>
<td>13</td>
<td>Rt shoulder droop &amp; decreased abduction; other Sxs: vertigo</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>12</td>
<td>1/1</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>NA</td>
<td>9</td>
<td>15</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>1/1</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>0</td>
<td>28</td>
<td>8</td>
<td>19</td>
<td>Normal; other Sxs: pulse synchronous tinnitus</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>14</td>
<td>1/1</td>
<td>1/0</td>
<td>0/0</td>
<td>1/0</td>
<td>0</td>
<td>0</td>
<td>26</td>
<td>18</td>
<td>17</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>15</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0/0</td>
<td>1/0</td>
<td>NA</td>
<td>50</td>
<td>42</td>
<td>NA</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>16</td>
<td>1/1</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>0</td>
<td>0</td>
<td>27</td>
<td>8</td>
<td>16</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>17</td>
<td>0/0</td>
<td>1/0</td>
<td>0/0</td>
<td>0/0</td>
<td>1/0</td>
<td>NA</td>
<td>32</td>
<td>NA</td>
<td>NA</td>
<td>Normal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>18</td>
<td>1/1</td>
<td>0/0</td>
<td>0/1</td>
<td>0/0</td>
<td>0</td>
<td>0</td>
<td>32</td>
<td>22</td>
<td>30</td>
<td>Normal; other Sxs: tingling in bilat finger tips</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Totals</td>
<td>16/14</td>
<td>13/7</td>
<td>7/0</td>
<td>3/1</td>
<td>3/0</td>
<td></td>
<td>16</td>
<td>1</td>
<td>1</td>
<td>16</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

HA = headache; NA = not available; Papill = papilledema; Sxs = symptom; 0 = absent; 1 = present.
ing procedure, with no patient experiencing residual tinnitus, papilledema, or auditory bruit. As previously noted, one patient (5.6%) had new-onset tinnitus postprocedure. As was the case in the studies previously mentioned, headache was the most common residual symptom in our patients; however, it was also the most common presenting symptom. One of our patients required a shunt for treatment, and the headaches improved after shunt insertion.

Postoperative LP was only performed in patients who experienced persistent symptoms following venous sinus stenting. Only 2 patients had persistent symptoms that they considered unimproved from pre-stenting. An LP was performed in these patients to determine their candidacy for further treatment. Of note, each of these patients had a significant decrease in the LP opening pressure despite a lack of improvement in their symptoms. A complete algorithm of our decision-making process is included in Fig. 3.

Our study demonstrated a level of safety similar to that in previous studies, with only 1 patient experiencing a failed procedure in which the catheter could not pass the transverse sinus and the procedure was aborted. Further investigation, including a prospective trial of this condition with long-term follow-up, is necessary to further elucidate the effectiveness of this technique.

Conclusions

Transverse sinus stenting is a rapidly developing technique that has shown good efficacy and safety in the literature. We also found that stenting of a stenotic transverse sinus in patients with IIH was a safe and overall effective therapeutic strategy. Further investigation, including a prospective trial with long-term follow-up, is necessary to further elucidate the effectiveness of this technique.

Acknowledgments

We thank Paul H. Dressel, BFA, for preparation of the illustrations and W. Fawn Dorr, BA, and Debra J. Zimmer for editorial assistance.

References

3. Dinkin MJ, Patsalides A: Venous sinus stenting for idiopathic
intracranial hypertension: where are we now? Neurol Clin 35:59–81, 2017

Disclosures
Dr. Davies has been a consultant for Neurotrauma Sciences, has served on the Data Safety and Monitoring Board for StrokeNet, and has been a KL-2 scholar. Dr. Morrison has received grants from NVIDIA Corp. and Google. Dr. Levy has shareholder/ownership interests in Intratech Medical Ltd., NeXtGen Biologics, Rapid Medical, Claret Medical, Cognition Medical, Rebound Thera, StimMed, and Three Rivers Medical Inc.; has been a consultant for Pulsar Vascular; has been on the advisory board for Stryker, NeXtGen Biologics, MEDX, Cognition Medical, and Endostream Medical; is the national principle investigator for SWIFT Prime and SWIFT Direct Trials; and is the site principle investigator for Microvention for the CONFIDENCE study. Dr. Siddiqui has financial interest/investor/stock options/ownership in Amnis Therapeutics, Apama Medical, BlinxTBI Inc., Buffalo Technology Partners Inc., Cardinal Health, Cerebrotech Medical Systems Inc., Cognition Medical, International Medical Distribution Partners, Rebound Therapeutics Corp., Synchron, Three Rivers Medical Inc., Viseon Spine Inc.; and has been a consultant for Amnis Therapeutics Ltd, Boston Scientific, Canon Medical Systems USA Inc, Cerenovus, Claret Medical, Corindus Inc., Endstream Medical Ltd., Guidepoint Global Consulting, Imperative Care, Integra, Medtronic, MicroVention, Penumbra, Rapid Medical, Rebound Therapeutics Corp., Silk Road Medical, StimMed, Stryker, Three Rivers Medical Inc., VasSol, and W.L. Gore & Associates. Dr. Snyder has been a consultant and teacher for Canon Medical Systems Corp., Penumbra Inc., Medtronic, and Jacobs Institute; and is the founder of Neurovascular Diagnostics Inc.

Author Contributions
Conception and design: Hess. Acquisition of data: all authors. Analysis and interpretation of data: all authors. Drafting the article: Cappuzzo, Hess. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors.

Correspondence
Adnan H. Siddiqui: University at Buffalo, Buffalo, NY. asiddiqui@ubns.com.